When a consumer-focused investment bank publishes a report titled 'The Impact and Opportunities of GLP-1s for the Fitness and Wellness Industry,' the industry should pay attention — and Matthew Januszek did. On this episode of Escape Your Limits, Matthew sits down with Paul Byrne, Partner at Harrison Co, to go deep on what GLP-1 weight-loss medications actually mean for gym operators, equipment companies, coaches, and the broader health and wellness sector. Byrne is one of the most credentialed voices in the room: over a twenty-year career, he transformed Precor from a single-product company into a globally recognized multi-product brand, launching the elliptical (EFX) and the adaptive motion trainer (AMT) and pioneering gym floor technology with the introduction of Preva, Precor's personalized cardio-machine platform.

The episode draws directly on the Harrison Co report, which Byrne was instrumental in developing, to work through the full range of GLP-1's implications: how the medications work, how people access them, what they mean for gym attendance and body composition, and where the most compelling commercial opportunities lie for fitness businesses willing to adapt. The conversation runs for over an hour — and earns every minute of it.

About Paul Byrne

Paul Byrne is a Partner at Harrison Co, a consumer-focused investment bank that advises clients on strategic decisions in a rapidly changing consumer economy. His firm's report on GLP-1 medications and their impact on the fitness and wellness industry is one of the more rigorous pieces of sector analysis to emerge from the GLP-1 conversation — grounded in financial and strategic expertise rather than the fitness industry's tendency toward either uncritical enthusiasm or existential alarm.

Byrne's authority on this topic is built on his decades at Precor, where he operated at the intersection of product innovation, consumer behavior, and changing market conditions in exactly the way that GLP-1 demands. His experience launching iconic fitness equipment innovations and spearheading Preva's gym floor technology revolution gives him a clear framework for assessing how fitness businesses should respond when a significant external force reshapes demand: study the disruption, find the opportunity, and act before the window closes.

The Harrison Co report that anchors this conversation is available at harrisonco.com and covers the rationale behind GLP-1 analysis, a definition of how these medications work and how they are accessed, their likely disruption of the fitness industry and other sectors (including weight loss, home fitness, and healthcare), and a detailed look at the commercial opportunities for operators who choose to lean in rather than wait and see.

What Paul Byrne and Matthew Januszek Talked About

• Byrne explains how GLP-1 receptor agonists work and how people currently access them — including through prescription healthcare providers and, increasingly, through retail channels — providing the factual foundation operators need before forming a strategic response. Nothing in this episode constitutes medical advice, and anyone considering GLP-1 use should consult their own healthcare provider.
• The episode makes a detailed case that GLP-1 adoption is likely to drive more people into gyms rather than fewer, because the medications create both a physical need (muscle preservation during rapid weight loss) and a psychological context (commitment to health improvement) that fitness facilities are uniquely positioned to address.
• Gym design and facility layout are identified as areas requiring adaptation: Byrne discusses the need for fitness environments that welcome and actively accommodate members who are obese or in early stages of significant weight change — a design and cultural challenge that many operators have not yet seriously engaged.
• Body composition, specifically the risk of losing muscle mass during GLP-1-driven weight loss, is examined as a critical issue that creates a clear mandate for resistance training and coach-led programming among GLP-1 users — and therefore a direct opportunity for gyms that can deliver that programming effectively.
• The opportunity for coaches to specialize in supporting GLP-1 users is explored as both a professional development pathway and a commercial differentiator: Byrne discusses the gap between what most fitness professionals currently know about these medications and what they need to know to serve this emerging client segment well.
• The fitness industry's opportunity to capitalize on GLP-1 requires intentional market segmentation, with Byrne arguing that operators who can clearly identify and program for defined member types — those pre-medication, on medication, post-medication, or medication-adjacent — will outperform those who apply a single generic response.
• The merging of fitness and wellness with traditional healthcare is presented as the structural shift that GLP-1 is accelerating, with Byrne and Matthew discussing how US healthcare costs, corporate wellness programs, and population health outcomes are creating conditions in which fitness businesses can position themselves as genuine partners to the healthcare system.

Why This Conversation Matters

Matthew Januszek has spent his career building fitness products and businesses at the frontier of where consumer demand is heading. His conversation with Paul Byrne is the kind of deep, research-grounded dialogue that the Escape Your Limits podcast was built for: not a surface summary of a trend, but a real examination of what operators need to understand and do. The GLP-1 moment is one of the most significant structural shifts the fitness industry has faced in a generation, and this episode gives it the seriousness it deserves.

For listeners building or running fitness businesses — whether as operators, investors, or equipment professionals — Byrne's combination of investment-banking analysis and fitness-industry credibility makes this one of the more actionable GLP-1 conversations available anywhere. The Harrison Co report itself is worth requesting; the episode is the guided tour.

▶  Watch the full episode on YouTube

Related Episodes & Interviews

• Ross Campbell →
• The Performance Medicine Era →
• GLP-1s and the Regain Effect →